N-803 for progressive sarcoma after T-cell therapy
Treatments studied
Part of Cancer clinical trials.
This trial tests a drug called N-803 for people with synovial sarcoma or myxoid/round cell liposarcoma that has gotten worse after T-cell therapy. N-803 may help the immune system fight the cancer, and the study will see if it can slow or stop the cancer from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have synovial sarcoma or myxoid/round cell liposarcoma that got worse after treatment with T-cell therapy (like Tecelra).
- You must have a tumor that can be measured on a scan and showed some benefit (stable or smaller) on at least one scan after the T-cell therapy.
- You must be between 18 and 80 years old.
- You must be able to care for yourself (performance status score of 70 or higher on Karnofsky scale, or 0 or 1 on ECOG scale).
- You must be able to undergo leukapheresis (a procedure to collect white blood cells).
- You must have adequate organ and bone marrow function, such as enough blood cell counts and healthy liver and kidneys.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests a new therapy for children and young adults with specific types of cancer that have been treated with chemotherapy before. It may help by targeting cancer features in the tumor and using your immune system in a controlled way.
This trial tests a combination of two medicines: one that trains your immune cells to find cancer (ACTengine IMA203) and another that helps the body recognize the tumor (mRNA-4203). It's for people with advanced melanoma or synovial sarcoma who have already tried other treatments.
This Phase 3 study tests two anti-cancer medicines (anlotinib and catequentinib) for people with certain advanced soft-tissue sarcomas, including alveolar soft part sarcoma, synovial sarcoma, and leiomyosarcoma. It is designed for tumors that cannot be removed and that have either grown despite treatment or no longer respond to standard options.
This trial tests a personalized treatment plan for children and young adults with a type of soft tissue sarcoma (NRSTS). It uses a combination of surgery, targeted radiation, and two drugs (pazopanib and selinexor) to fight cancer while reducing side effects. The study is looking for people who have not been treated before for this sarcoma.
This trial tests a new kind of immune therapy using your own natural killer (NK) cells that are specially trained to find and attack cancer cells that have the NY-ESO-1 target. It is for people with certain sarcomas or other advanced solid tumors that have not responded to prior treatments.
This trial tests a new immune cell therapy (MASCT-I) combined with standard chemotherapy (doxorubicin and ifosfamide) for people with advanced soft tissue sarcoma who have not had prior chemotherapy or targeted therapy. The goal is to see if the combination works better than chemo alone.
Hear when a new Myxoid Liposarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.